11β-Hydroxysteroid dehydrogenase type 1 contributes to the balance between 7-keto- and 7-hydroxy-oxysterols <i>in vivo</i> by Mitić, Tijana et al.
 
 
University of Birmingham
11-Hydroxysteroid dehydrogenase type 1
contributes to the balance between 7-keto- and 7-
hydroxy-oxysterols in vivo
Miti, Tijana; Shave, Steven; Semjonous, Nina; Mcnae, Iain; Cobice, Diego F.; Lavery, Gareth
G.; Webster, Scott P.; Hadoke, Patrick W.f.; Walker, Brian R.; Andrew, Ruth
DOI:
10.1016/j.bcp.2013.02.002
License:
Creative Commons: Attribution (CC BY)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Miti, T, Shave, S, Semjonous, N, Mcnae, I, Cobice, DF, Lavery, GG, Webster, SP, Hadoke, PWF, Walker, BR &
Andrew, R 2013, '11-Hydroxysteroid dehydrogenase type 1 contributes to the balance between 7-keto- and 7-
hydroxy-oxysterols in vivo', Biochemical Pharmacology, vol. 86, no. 1, pp. 146-153.
https://doi.org/10.1016/j.bcp.2013.02.002
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
Eligibility for repository : checked 6/08/2014
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Mar. 2020
Biochemical Pharmacology 86 (2013) 146–15311b-Hydroxysteroid dehydrogenase type 1 contributes to the balance
between 7-keto- and 7-hydroxy-oxysterols in vivo
Tijana Mitic´ a, Steven Shave b, Nina Semjonous c, Iain McNae b, Diego F. Cobice a,
Gareth G. Lavery c, Scott P. Webster a, Patrick W.F. Hadoke a, Brian R. Walker a, Ruth Andrewa,*
a Endocrinology, University/British Heart Foundation Centre for Cardiovascular Science, The Queen’s Medical Research Institute, University of Edinburgh,
Edinburgh, EH16 4TJ, UK
b Institute of Structural and Molecular Biology, King’s Buildings, University of Edinburgh, Edinburgh, EH9 3JR, UK
cCentre for Endocrinology, Diabetes and Metabolism, School of Clinical & Experimental Medicine, University of Birmingham, Birmingham, B15 2TT, UK
A R T I C L E I N F O
Article history:
Received 18 December 2012
Accepted 4 February 2013
Available online 13 February 2013
Keywords:
7-Oxysterols
7b-Hydroxycholesterol
7-Ketocholesterol
Glucocorticoids
11b-Hydroxysteroid dehydrogenase 1
Corticosterone
A B S T R A C T
11b-Hydroxysteroid dehydrogenase 1 (11bHSD1; EC 1.1.1.146) generates active glucocorticoids from
inert 11-keto metabolites. However, it can also metabolize alternative substrates, including 7b-
hydroxy- and 7-keto-cholesterol (7bOHC, 7KC). This has been demonstrated in vitro but its
consequences in vivo are uncertain. We used genetically modiﬁed mice to investigate the contribution
of 11bHSD1 to the balance of circulating levels of 7KC and 7bOHC in vivo, and dissected in vitro the
kinetics of the interactions between oxysterols and glucocorticoids for metabolism by the mouse
enzyme.
Circulating levels of 7KC and 7bOHC in mice were 91.3  22.3 and 22.6  5.7 nM respectively,
increasing to 1240  220 and 406  39 nM in ApoE/mice receiving atherogenic western diet. Disruption of
11bHSD1 in mice increased (p < 0.05) the 7KC/7bOHC ratio in plasma (by 20%) and also in isolated
microsomes (2 fold). The 7KC/7bOHC ratio was similarly increased when NADPH generation was restricted
by disruption of hexose-6-phosphate dehydrogenase.
Reduction and oxidation of 7-oxysterols by murine 11bHSD1 proceeded more slowly and substrate
afﬁnity was lower than for glucocorticoids. in vitro 7bOHC was a competitive inhibitor of oxidation of
corticosterone (Ki = 0.9 mM), whereas 7KC only weakly inhibited reduction of 11-dehydrocorticosterone.
However, supplementation of 7-oxysterols in cultured cells, secondary to cholesterol loading,
preferentially slowed reduction of glucocorticoids, rather than oxidation.
Thus, in mouse, 11bHSD1 inﬂuenced the abundance and balance of circulating and tissue levels of
7bOHC and 7KC, promoting reduction of 7KC. In health, 7-oxysterols are unlikely to regulate
glucocorticoid metabolism. However, in hyperlipidaemia, 7-oxysterols may inhibit glucocorticoid
metabolism and modulate signaling through corticosteroid receptors.
 2013 Elsevier Inc. All rights reserved.
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jo u rn al h om epag e: ww w.els evier .c o m/lo cat e/bio c hem p har m1. Introduction
Intracellular generation of active glucocorticoids (cortisol in
humans, corticosterone in mice) is catalyzed by 11b-hydroxyster-
oid dehydrogenase (11bHSD) type 1 (EC 1.1.1.146). The potential
for 11bHSD1 to regulate fuel metabolism has been demonstrated
in murine models, in which disruption of the enzyme protects from
metabolic dyshomeostasis [1,2] and, more recently, in humans in* Corresponding author. Tel.: +44 131 242 6763; fax: +44 131 242 6779.
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http://dx.doi.org/10.1016/j.bcp.2013.02.002whom speciﬁc 11bHSD1 inhibitors improve hyperglycaemia [3]. In
murine models, inhibition of 11bHSD1 also offers atheroprotec-
tion [4–6]. Therefore inhibition of the reductase activity of
11bHSD1 is a tractable target for drug development, but to fully
understand the spectrum of actions and side-effects of such drugs,
effects on other substrates of 11bHSD1 must be considered. This is,
as yet, unexplored in vivo, either in genetically modiﬁed mice or
following selective pharmacological manipulation.
In addition to metabolizing glucocorticoids, 11bHSD1 can
catalyze the inter-conversion of 7-keto- and 7b-hydroxy-sterols
and steroids (Fig. 1a) (e.g. 7-oxygenated metabolites of dehydro-
epiandrosterone [7] and highly cytotoxic cholesterol metabolites,
the 7-oxysterols [8,9]). 7-Oxysterols are formed from cholesterol
both enzymatically and by auto-oxidation [10]. They accumulate
in atherosclerotic plaques, a site of 11bHSD1 expression [11], with
7-ketocholesterol (7KC) being the most abundant, closely followed
Fig. 1. (a) Interconversion of glucocorticoids and 7-oxysterols catalyzed by 11b-
hydroxysteroid dehydrogenase type 1 (11bHSD1). The equilibrium of
interconversion of inert 11-keto and active 11b-hydroxy forms of
glucocorticoids (shown here as 11-dehydrocorticosterone and corticosterone, the
principle rodent glucocorticoids) favors predominant reduction. 11bHSD1 can also
interconvert 7-keto and 7b-hydroxycholesterol but the favored equilibrium
position between the two reactions is not understood. (b)–(e) In Silico modeling
of interactions between 7-oxysterols and residues in the active site of murine 11b-
hydroxysteroid dehydrogenase 1 (m11bHSD1). 2D Modeling of the active site of
m11bHSD1 (retrieved from PDB 1Y5 M) using LigPlot. Hydrogen bond lengths of
interactions between (b) 7-ketocholesterol and (c) 7b-hydroxycholesterol and the
critical residues of catalytic tetrad are shorter than those for (d) 7a-
hydroxycholesterol (7aOHC). (e) 3D modeling of interactions between active
site residues Serine 170 (S170) and Tyrosine 183 (Y183) of m11bHSD1 and the 7-
oxygenated moieties using PyMOL. Positioning of 7bOHC (pink) or 7KC (yellow)
into the active site demonstrated their more favorable orientation over 7aOHC
(turquoise), for hydrogen bonding with key amino acids of m11bHSD1 active site.
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revealed that 11bHSD1 converted 7bOHC to 7KC in hepatic
microsomes from all vertebrates tested (human, guinea-pig, rat,
hamster and chicken) and that rat hepatic 11bHSD1 also reduced
7KC to 7bOHC. However, this has not been studied in other species
and it remains unclear whether enzymes other than 11bHSD1 also
catalyze interconversion of 7bOHC and 7KC.
11bHSD1 is a bi-directional enzyme (Fig. 1a) and both
dehydrogenase (inactivating glucocorticoids) and reductase(regenerating glucocorticoids) activities can be measured in
tissues [15,16]. The prevalent direction of 11bHSD1, with respect
to metabolism of glucocorticoids, is reduction and is dependent on
the availability of endogenous co-factor (NADPH), which is
generated by hexose-6-phosphate dehydrogenase (H6PDH) within
the endoplasmic reticulum (ER) [17]. Mice lacking H6PDH are
unable to regenerate glucocorticoids by 11bHSD1 [18] but it is
unclear if NADPH supply physiologically regulates the balance
between reductase and dehydrogenase activities and the contri-
bution of H6PDH in vivo has not been investigated for 7-oxysterols.
Pharmacological inhibition of 11bHSD1 in rats caused hepatic
accumulation of 7KC [9] suggesting that, as with glucocorticoids,
the predominant direction of metabolism of 7-oxysterols by
11bHSD1 in vivo is reduction. Tissue-speciﬁc differences in the
equilibrium position of metabolism of glucocorticoids by
11bHSD1 may indeed be due to the presence of competitive
substrates, as some reports have suggested that 7-oxygenated
compounds inhibit metabolism of glucocorticoids by 11bHSD1
[19]. For example, 7KC and 7bOHC inhibit 11bHSD1 activity in
mouse adipocyte (3T3-L1 and 3T3-F442) cell lines [20] and in
differentiated human THP-1 macrophages [21], modulating the
downstream actions of glucocorticoids.
We hypothesized that 11bHSD1 is a key determinant of the
balance of 7bOHC and 7KC in vivo. Depending on their levels in the
circulation and tissues, 7KC and 7bOHC may differentially inhibit
either reduction or dehydrogenation of glucocorticoids, respec-
tively. Since these oxysterols accumulate in tissues that express
11bHSD1 [10] (e.g. macrophages, foam cells, adipose, atheroscle-
rotic plaques [11]), the relative proportion of 7KC to 7bOHC may
inﬂuence the amount of active glucocorticoid within cells. To
address this hypothesis we investigated the balance of 7KC and
7bOHC in mice with transgenic disruption of 11bHSD1 and
H6PDH, and abilities of these 7-oxysterols to inﬂuence the
equilibrium between the dehydrogenase and reductase activities
of glucocorticoid metabolism by murine 11bHSD1.
2. Materials and methods
Unless otherwise stated, solvents were HPLC grade (Fisher,
Hemel Hempstead, UK) and contained an anti-oxidant (0.01%w/v
butylated hydroxytoluene (BHT)). Steroids and oxysterols were
from Steraloids (Newport, Rhode Island, USA), derivatization
reagents from Fluka (Buchs, Switzerland), tissue culture reagents
from Lonza (Reading, UK) and other chemicals from Sigma–Aldrich
(Poole, UK). Tritiated 11-dehydrocorticosterone (11-DHC) was
synthesized [22] from [1,2,6,7-3H]4-corticosterone (GE Healthcare,
Bucks, UK). Deuterium-labeled internal standards [25,26,26,
26,27,27,27-2H]7-7KC, [25,26,26,26,27,27,27-
2H]7-7bOHC and
[25,26,26,26,27,27,27-2H]7-cholesterol were from CDN Isotopes
(Essex, UK). Protein concentrations were quantiﬁed using a Bio-
Rad kit (Hemel Hempstead, UK).
2.1. Animals
Male mice (10–16 weeks, n = 6–8/group [2,23]) with disruption
of 11bHSD1 (Hsd11b1/) or H6PDH (H6pdh/) or both
(Hsd11b1//H6pdh/) and their wild-type littermate controls
(15 weeks) were maintained on chow diet and tap water ad
libitum, under a 16 h/8 h light/dark cycle at 21–24 8C. Male ApoE/
 mice (in-house colony, 8 weeks; n = 6) were maintained on a
western Diet (D12079B, Research Diets, USA) for 14 weeks. All
licensed procedures were performed under accepted standards of
humane animal care, as outlined in the UK Home Ofﬁce Ethical
Guidelines. Animals were culled by cervical dislocation at 10:00 h.
Tissues and ﬂuids were snap-frozen and stored at 80 8C.
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HEK293 cells stably expressing full-length murine 11bHSD1
(m11bHSD1) [24] were maintained in Dulbecco’s Modiﬁed Eagle
Medium (DMEM) and seeded on poly-D-lysine coated (50 mg/mL,
5 min) plates. Medium was supplemented with glutamine
(2 mM), penicillin (100 units/mL), streptomycin (100 mg/mL),
and heat-inactivated fetal calf serum (10%v/v). For assessment of
kinetic parameters, stripped fetal calf serum, prepared with
dextran-coated charcoal (1% w/v), was added to the cells 12 h
prior to use. For manipulation of cholesterol, medium was
replaced with serum free medium 1 h prior to experimentation.
Cells were maintained in a humidiﬁed atmosphere (5%CO2, 95%
air, 37 8C).
2.3. Quantitation of 11bHSD1 enzyme kinetics
Inter-conversion of substrates and products was quantiﬁed
under conditions of ﬁrst order kinetics. Three forms of murine
enzyme (n = 6/group) were used: (1) a truncated form of
recombinant m11bHSD1 protein (N23D, gift from Dr Webster),
(2) enzyme contained within murine hepatic microsomes and (3) a
full-length m11bHSD1 protein expressed in stably transfected
HEK293 cells [24].
2.3.1. Metabolism by puriﬁed and microsomal murine 11bHSD1
Recombinant (14–28 mg/mL) or murine hepatic microsomal
(240–260 mg/mL [19]) protein was incubated (30 min, 37 8C) with
7-oxysterols (0.02–20 mM) in potassium phosphate buffer (0.1 M,
0.1 mM EDTA, 20 mM cysteamine hydrochloride, pH 7.4), or with
steroids (0.02–20 mM) in Krebs-Ringer buffer (containing 5 mM
glucose), and the relevant cofactor (2 mM) for oxidation (NADP+ or
NAD+) or reduction (NADPH or NADH). Similar experiments were
performed in hepatic microsomes from Hsd11b1/ mice [2]
(substrate 0.2 mM) with and without induction of cationic
permeability by alameticine (0.25 mM, 1–2 h). Reactions did not
proceed in the absence of either protein or the co-factor.
Following incubation, internal standards (epi-cortisol for
steroids or 19-hydroxycholesterol (19OHC, 100 ng) and 4a-
cholesten-7a-ol-3-one (50 ng) for oxysterols) were added after
stopping the reaction with addition of ethyl acetate (steroids;
10 vol) or petroleum ether (oxysterols; 10 vol). Organic extracts
were reduced to dryness under oxygen free nitrogen (60 8C) or
argon (room temperature), respectively, and the residues stored at
20 8C until analysis by HPLC.
2.3.2. Metabolism by recombinant murine 11bHSD1 expressed in
stably transfected cells
HEK293 cells, stably transfected to produce m11bHSD1, were
seeded onto a 5 cm dish and incubated overnight with 7KC,
7bOHC or 7aOHC (1 mM), or with steroid (30 nM) for 45 min.
Following addition of internal standard, as above, oxysterols
were extracted from the medium into 2-propanol:hexane (40:60,
9 mL, 50 mg/mL BHT) [25]. Dried organic residues were stored at
20 8C until analysis by gas chromatography mass spectrometry
(GCMS). Reactions did not proceed in non-transfected HEK293
cells.
2.4. Competition between 7-oxysterols and glucocorticoids for
metabolism by 11bHSD1
Recombinant protein (20 mg/mL) was incubated, as above, in
the presence of 11-DHC (0.5–10 mM) or corticosterone (0.025–
0.2 mM) and 7KC (0.02–20 mM) or 7bOHC (0.02–10 mM). Murine
hepatic microsomes (260 mg/mL) were incubated, as above, with
steroid (0.2 mM) in the presence of 7bOHC or 7KC (0.1 nM-5 mM).The velocity of metabolism of steroids (0.02–5 mM) was further
assessed in the presence of 7-oxysterols at their IC50 concentration
(vehicle, 0.01% v/v ethanol). HEK293 cells expressing m11bHSD1
were cultured, as above, and incubated with [3H]4-labeled (5 nM)
and unlabelled (25 nM) steroid and 7bOHC or 7KC or other
oxysterols (7a-, 19-, 22R- or 27-OHC; 1 nM-5 mM, 0.01% v/v
ethanol control).
2.5. Supplementation of cholesterol in stably transfected cells
To enrich cellular cholesterol and 7-oxysterol content, HEK293
cells stably expressing m11bHSD1 were incubated (37 8C, 30 min)
with cholesterol-loaded methyl-b-cyclodextrin (1:6, 10 mM in
DMEM) [26]) and kinetic experiments performed within 24 h.
Following manipulation, cells were washed with DMEM (37 8C)
followed by phosphate buffered saline, and then incubated
(5  106 cells/well, 1 h) in serum-free DMEM containing either
[3H]4-corticosterone or [
3H]4-dehydrocorticosterone (30 nM). Pro-
ducts of metabolism were quantiﬁed in medium by HPLC.
Following incubation, cells were washed with ice-cold PBS and
then lysed by gently rocking with NaOH (200 mM, 0.6 mL/well,
15 min, 4 8C) [27]. An aliquot of lysate was retained for
quantitation of protein. To the remaining cellular lysate, internal
standards [2H]7-7KC, [
2H]7-7bOHC (50 ng) and [
2H]7-cholesterol
(1 mg) were added and oxysterols and cholesterol were immedi-
ately extracted into methanol:hexane (2:5, 7 mL, 50 mg/mL BHT,
2 mM EDTA). The dried organic extract was dissolved in chloro-
form: methanol (2:1) and processed for quantitation by GCMS. All
ﬁnal measurements were expressed as a ratio of the total protein
content in the cells.
2.6. Quantitation of circulating and tissue levels of 7-oxysterols
7-Oxysterols were quantiﬁed in plasma (0.4–1 mL) prepared
from trunk blood collected (pooled if necessary) in EDTA-coated
tubes from mice (n = 8/group). Plasma was prepared from blood
collected in EDTA-coated (1.6 mg/mL) vials. The effects of
disruption of Hsd1b1, H6pdh or both were explored in hepatic
microsomes and cytosol (0.05–0.5 mg/mL protein) from mice
homozygous for the disrupted allele (n = 6/group) versus their
littermate controls. All samples were ﬂushed under argon prior to
extraction and BHT (45 mM, in ethanol) added before 7-oxysterols
were extracted and converted to their trimethylsilyl derivatives
[28] prior to analysis by GCMS [29].
2.7. Quantitation of steroids and oxysterols by HPLC
Substrates and products in in vitro extracts were analyzed by
HPLC (Dionex SUMMIT1 system, Camberley UK) with online
radioscintillation detection (LB5091 b-scintillation counter,
Berthold Technologies GmbH & Co, Germany). 7-Oxysterols
were eluted from a SUNFIRE1 column (C18, 15 cm, 4.6 mm,
5 mm; Waters, Edinburgh, UK) with acetonitrile:water (95:5), at
1 mL/min, 24 8C and quantiﬁed at selected wavelengths
(195 nm (7KC, 4a-cholesten-7a-ol-3-one), 237 nm (hydroxy-
cholesterols)). Glucocorticoids were separated using a SYMME-
TRY1 C8 column maintained at 35 8C (15 cm, 4.6 mm, 5 mm,
Waters) using a mobile phase of water:acetonitrile:methanol
(60:15:25) ﬂowing at 1 mL/min. Unlabelled steroids were
detected at 240 nm. Unlabelled oxysterols and steroids were
quantiﬁed by interpolation onto a standard curve of peak
area divided by that of the internal standard vs concentration,
prepared from calibration standards processed simultaneously.
Abundances of tritiated steroids were quantiﬁed by on-line
liquid scintillation counting (2 mL/min; GOLDFLOW1, Meridian,
Surrey, UK).
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residues in the active site of murine 11b-hydroxysteroid
dehydrogenase 1 (m11bHSD1)
3D Macromolecular structural information about m11bHSD1
was obtained from the Research Laboratory for Structural
Bioinformatics Protein Data Bank. 1Y5 M represented a dimeric
m11bHSD1 bound with NADP+ and 1Y5R represented m11bHSD1
bound with NADP+ and corticosterone [30]. The structure of 7a-
hydroxysteroid dehydrogenase (EC1.1.1.159, 7aHSD, PDBID
1FMC) in complex with 7-oxoglycochenodeoxycholic acid [31]
was a template for modeling the steric orientation of 7aOHC,
allowing alignment of 7a- and 7b-hydroxyl and 7-keto groups into
the active site, when 7aHSD and 11bHSD1 were subsequently
superimposed. Energy maps for all ligand atoms around the active
site were generated using the virtual screening program LIDAEUS
(Ligand Discovery At Edinburgh University). Energy minimization
routines were used to aid the positioning of substrate within the
active site of 11bHSD1. 2D Representations of protein-ligand
complexes from modeled structures were created using LigPlot
(Cambridge, UK), the output of which was then augmented by 2D
representations of substrates generated by MARVINVIEW1
(ChemAxon, Budapest, Hungary) to distinguish between the steric
orientation of 7a- and 7bOHC. Visualization of 3D structures was
performed using PyMOL (open source, DeLano Scientiﬁc LLC).
2.9. Analysis of kinetics and statistics
Vmax, Km and Ki values were determined, using global nonlinear
regression, from data generated by measuring reaction velocity
across a range of substrate concentrations in the absence and
presence of competitor. In addition, using recombinant protein,
Dixon Plots were generated as the reciprocal of the reaction
velocity using four substrate concentrations [S] against four
inhibitor concentrations [I]. All data are presented as mean  SEM.
SEM. Non-linear regression and statistical comparisons were made
using GRAPHPAD PRISM1 software v5.0 (GraphPad Software Inc. San
Diego, USA) by 1 or 2-way ANOVA (with Tukey post hoc tests), or
unpaired or paired Student’s t-tests as appropriate.
3. Results
3.1. Disruption of 11bHSD1 or H6PDH in vivo impairs reduction of
7-oxysterols
7-Oxysterols were present in plasma from wild-type, littermate
control mice in concentrations of 91.3  22.3 (7KC) and 22.6  5.7
(7bOHC) nM [29]. Levels increased more than 10 fold (1240  22
(7KC) and 406  39 (7bOHC) nM) in ApoE/mice on an atherogenic,
western diet. Following disruption of Hsd11b1, there was a trend
(p = 0.08) for an increase in concentrations of 7KC (133.8  16.8 nM)
but not 7bOHC (23.6  2.2 nM) [29]. However, the ratio ofTable 1
Effect of disruption of Hsd1b1 or H6pdh on 7-oxysterol concentrations in hepatic micro
Control Hsd11b1/
7bOHC 84.45  27.55 16.10  5.20**
7KC 22.45  8.20 10.01  2.85*
7KC/7bOHC 0.31  0.14 0.65  0.04*
Disruption of either 11b-hydroxysteroid dehydrogenase 1 (Hsd11b1/) or hexose-
hydroxycholesterol (7bOHC) to a greater extent than 7-ketocholesterol (7KC) in hepatic
enzymes (Hsd11b1/, H6pdh/) did not have any additional effect on the levels of 7-oxy
1-way ANOVA, and Tukey’s post hoc test, n = 4–6.
* p < 0.05.
** p < 0.01 vs. control.
# p < 0.05 compared with H6pdh/.7KC/7bOHC in plasma signiﬁcantly increased in the Hsd11b1/
(5.4  0.5) vs. control mice (4.1  0.4, n = 9, p < 0.05).
Both 7KC and 7bOHC were detected in microsomes from control
mice. Disruption of Hsd11b1 caused a profound reduction in hepatic
microsomal concentrations of both oxysterols (Table 1), with an
increase in the 7KC/7bOHC ratio. In the cytosols from control murine
liver, only 7KC (25.3  13.4 ng/mg protein) was detected, but
following disruption of 11bHSD1, levels of 7KC became undetectable.
Disruption of H6pdh, or both H6pdh and Hsd1b1 also lowered the levels
of 7bOHC and 7KC in the hepatic microsomes compared with
littermate controls (Table 1). The 7KC/7bOHC ratio increased with
disruption of H6pdh and disruption of both H6pdh and Hsd11b1 did not
have any further effect over lack of 11bHSD1 alone (Table 1).
3.1.1. Oxysterols Inhibit oxidation and/or reduction of glucocorticoids
Competition between 7-oxysterols and glucocorticoids for
metabolism by 11bHSD1 across physiological and pathophysio-
logical concentration ranges was investigated using three pre-
parations of murine enzyme. In all preparations, 7aOHC was not
accepted as a substrate and not generated upon reduction of 7KC
(not shown).
3.1.2. Murine 11bHSD1 stably transfected into HEK293 cells
Both oxidation and reduction of glucocorticoids were detected
in vitro, and reduction was the preferred direction (0.79  0.15
(oxidation) vs. 3.86  0.27 (reduction) pmol/mg/min, respectively,
with 30 nM substrate). Both oxidation of 7bOHC and reduction of
7KC, were observed, at similar velocities, which were considerably
slower than those measured for glucocorticoids. For example,
substrate concentrations of 1 mM were required to achieve rates of
oxidation of 7bOHC and reduction of 7KC of 0.90  0.31 vs
0.74  0.04 pmol/mg/min, respectively. Inhibition of metabolism of
glucocorticoids by a range of endogenous oxysterols was assessed in
both reductase and dehydrogenase directions. 7KC caused the most
marked inhibition of reduction of all oxysterols tested, although still
only by 40% at the highest concentration used (100 mM; Fig. 2a) and
further kinetic analysis was not performed. Of the different oxysterols
tested, only 7bOHC inhibited oxidation of corticosterone, with a Ki of
1.77  0.09 mM (Fig. 2b).
3.1.3. Murine recombinant 11bHSD1
Although both oxidation and reduction of glucocorticoids were
detected using recombinant 11bHSD1, reduction of 11-DHC was
the favored reaction (lower Km and higher Vmax, Table 2). Oxidation
of 7bOHC and reduction of 7KC were also detected but proceeded
with slower maximal rates and these substrates had poorer afﬁnity
(higher Kms; Table 2) than glucocorticoids. 7KC inhibited reduction
of 11-DHC (Fig. 2c) with a Ki of 7.33  1.76 mM, and 7bOHC
inhibited dehydrogenation of corticosterone with a Ki of
0.91  0.05 mM. (Fig. 2d). In both cases, the nature of inhibition
was competitive, indicated by the regression lines of the Dixon Plots
intercepting above the x-axis.somes.
H6pdh/ Hsd11b1//H6pdh/
12.12  2.34** 21.44  3.50*,#
7.78  1.68* 14.76  2.64*,#
0.63  0.01* 0.68  0.04**
6-phoshate dehydrogenase (H6pdh/) reduced levels (ng/mg protein) of 7b-
 microsomes compared with littermate control (C57BL/6) mice. Disruption of both
sterols over lack of 11bHSD1 or H6PDH alone. Data are mean  SEM, compared using
Fig. 2. 7-Oxysterols inhibit the metabolism of glucocorticoids by 11b-hydroxysteroid
dehydrogenase 1 (11bHSD1). (a) and (b): The velocities of (a) reduction of 11-
dehydrocorticosterone (11-DHC) to corticosterone and (b) oxidation of corticosterone
to 11-DHC were quantiﬁed following incubation of HEK293 cells (stably transfected to
generate murine 11bHSD 1) with a range of concentrations of oxysterols. Non-linear
regression was used to assign IC50 values. 7-Ketocholesterol (7KC) only inhibited the
reduction of 11-DHC by 40%. 7b-Hydroxycholesterol (7bOHC) completely inhibited
oxidation ofcorticosterone; other oxysterols did not have aneffect. Data (mean  SEM)
are % control (absence of oxysterol), n = 6 for 7-oxysterols and n = 3 for other oxysterols.
OHC = hydroxycholesterol. (c)–(f) 7-Oxysterols inhibited metabolism of glucocorticoids
by recombinant and microsomal 11bHSD1; in both cases they inhibited dehydrogenation
more potently than reduction. Competitive inhibition of (c) reduction of 11-DHC to
corticosterone in the presence of 7KC and (d) oxidation of corticosterone to 11-DHC in the
presence of 7bOHC, by recombinant 11bHSD1, demonstrated by Dixon Plots (mean data).
Inhibition of (e) reduction of 11-DHC to corticosterone in the presence of 7KC and (f)
oxidation of corticosterone to 11-DHC in the presenceof 7bOHC by microsomal 11bHSD1.
n = 3–7. (g) Supplementation of cholesterol impeded reduction of glucocorticoids by
11bHSD1. The velocity of reduction of 11-DHC (open bars) by 11bHSD1 stably transfected
in HEK293 was suppressed when 7-oxysterol levels were supplemented by delivery of a
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Both oxidation and reduction of glucocorticoids were detected
using microsomal 11bHSD1 with reduction being the preferred
direction (lower Km and higher Vmax, Table 2). In contrast, only
oxidation of 7bOHC could be measured, forming 7KC at the same
rate in the presence of either NAD+ or NADP+ (e.g. 1.25  0.2 vs.
1.35  0.4 pmol/mg/min respectively; 20 mM substrate, n = 3). This
reaction was dependent on the presence of 11bHSD1, as 7bOHC was
not converted to 7KC by hepatic microsomes from Hsd11b1/ mice,
with either cofactor. Again, 7-oxysterols demonstrated poorer afﬁnity
than glucocorticoids for 11bHSD1. The Km for oxidation of 7bOHC was
approximately three orders of magnitude higher than that for
glucocorticoids (Table 2), although the maximal velocities achieved
were similar for glucocorticoids and 7-oxysterols. Reduction of 7KC
could not be demonstrated, even following the addition of the
permeabilisation agent, alameticine, or use of NADH as an alternative
cofactor [32]. 7KC weakly inhibited reduction of 11-DHC with an IC50 of
19.4  1.2 mM (Fig. 2e) and further kinetic analysis was not performed.
7bOHC inhibited oxidation with an IC50 of 2.2  0.4 mM (Fig. 2f).
3.2. Supplementation of cellular content of cholesterol and 7-
oxysterol impedes reduction of glucocorticoids by 11bHSD1
The effect of cholesterol loading was assessed on the equilibri-
um of 11bHSD1 stably transfected into HEK293 cells. 7KC
(19.4  1.08 pmol/mg) and 7bOHC (4.37  1.90 pmol/mg) were
present in cells treated with vehicle. Cholesterol loading signiﬁcantly
(p < 0.05) increased the levels of 7KC (39.48  3.01 pmol/mg) and
7bOHC (17.6  2.4 pmol/mg), associated with a slower velocity of
reduction of glucocorticoids by 11bHSD1 compared with vehicle-
treated cells (Fig. 2g).
3.3. In silico modeling
3.3.1. 2D modeling
A representation of m11bHSD1 (PDB structure 1Y5R) was
created to predict proximity of interactions of steroids and 7-
oxysterols with resident cofactor (NADP+/NADPH) and the
tyrosine (Tyr183) and serine (Ser170) residues of the catalytic
tetrad (Tyr183-Ser170-Lys187-Asn143) (Figs. 1(b)–(d)) [33]. Dis-
tances of hydrogen bonds from the active C7 oxygen on 7-
oxysterols to Ser170 and Tyr183 residues were shortest for 7bOHC
(2.7, 2.8 A˚ respectively), longer for 7KC (3.2, 3.3 A˚) and longest for
7aOHC (4.5, 3.5 A˚). Distances of 7bOHC and 7KC were comparable
to those of glucocorticoids (B, 3.0, 3.2; A, 2.8, 2.6 A˚ respectively).
Interactions with the co-factor were similar for all three 7-
oxysterols (all 3.0 A˚; corticosterone 3.9, 11-DHC, 3.3 A˚).
3.3.2. 3D in silico modeling
7-Oxysterols have not been co-crystallised with 11bHSD1.
Thus, to establish the spatial orientation of the oxygenated
residues at the C7 position, the structure of the closely related
7aHSD in complex with 7-oxoglycochenodeoxycholic acid (1FMC)
was used. Tyrosine residues in the active sites of 7aHSD (1FMC)
and m11bHSD1 (1Y5R) could be superimposed, allowing the 7a-
hydroxyl group of 1FMC ligand to overlay the 11b-hydroxyl group
of corticosterone docked within 1Y5R. Thus, the 3D structure of
7aOHC was created to resemble that of 7-oxoglycochenodeoxy-
cholic acid, allowing the positions of the 7b-hydroxyl and 7-keto
groups of 7bOHC and 7KC respectively to be orientated. 7-
Oxysterols were docked into the active site of 1Y5R and 3D
representations shown in Fig. 1e. The A-ring of 7-oxysterols (as
opposed to the D-ring of glucocorticoids) was orientated towardcomplex of cholesterol and methyl-b-cyclodextrin (1:6). *p < 0.01 compared by 2 way
ANOVA with Bonferroni post-test, n = 6.
Table 2
Kinetic parameters describing metabolism of 7-oxysterols and glucocorticoids by murine 11b-hydroxysteroid dehydrogenase 1 (11bHSD1).
Substrate Km (mM) Vmax Vmax/Km
Recombinant protein
11-Dehydrocorticosterone Reduction 0.20  0.25 8.56  4.06 42.8
7-Ketocholesterol Reduction 1 269  282 0.12  0.03 9  105
Corticosterone Oxidation 1.78  0.56 4.82  0.65 2.7
7b-hydroxycholesterol Oxidation 327.60  98.50 0.010  0.001 3  105
Microsomes
11-Dehydrocorticosterone Reduction 1.30  0.54 1.19  0.18 0.9
7-Ketocholesterol Reduction Product not detected
Corticosterone Oxidation 4.20  2.01 0.04  0.01 0.01
7b-hydroxycholesterol Oxidation 3 500  326 0.03  0.001 9  106
Velocities of metabolism of substrates by murine recombinant or microsomal 11bHSD1 were assessed and kinetic parameters (Km, Vmax and Vmax/Km, true or apparent)
assigned following Lineweaver-Burke transformation of data ﬁtted to Michaelis-Menten kinetics. The velocities were quantiﬁed; for reduction of 11-dehydrocorticosterone
or 7-ketocholesterol in the presence of NADPH or oxidation of corticosterone or 7b-hydroxycholesterol in the presence of NADP+. Data are mean  SEM, obtained from at least
three independent experiments. Vmax expressed as pmol/mg/min. Vmax/Km expressed as L/mg/min  106.
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7bOHC and Ser170 and Tyr183 of the catalytic tetrad had the
shortest bond distances (2.7, 2.8 A˚ respectively), followed by those
of 7KC (3.2, 3.3 A˚) and then 7aOHC (4.5, 4.8 A˚; for comparison
corticosterone 3.1, 2.8 A˚ [30]; 11-DHC 2.8, 2.6 A˚ respectively)
When 7bOHC and 7KC were docked, the Tyr183 residue was 5.1 A˚
from the nicotinamide C4 and Lys187 was 3.2 A˚ from the hydroxyl
group on the cofactor. When 7aOHC was docked, the Tyr183
residue was 4.20 A˚ from the nicotinamide C4 and Lys187 was 3.2 A˚
from the hydroxyl group on the cofactor.
4. Discussion
These data demonstrate that reduction of 7KC to 7bOHC is the
preferred direction of metabolism of 7-oxtserols by 11bHSD1 in
vivo in mouse. Metabolism of 7-oxysterols (at least dehydrogena-
tion) was not detected in microsomes of 11bHSD1 null mice,
supporting the notion that it is the only enzyme catalyzing this
reaction. While 7-oxysterols were competitive inhibitors of
metabolism of glucocorticoids by 11bHSD1, it is unlikely that in
health [34] they will be sufﬁciently potent to exert this effect.
Inhibition may become important in hyperlipidaemia [10], or at
sites where oxysterols accumulate, such as in adipose and
atherosclerotic lesions.
Structural modeling of the murine protein conﬁrmed the
potential for interactions of 7-oxysterols with the catalytic tetrad
of the enzymatic active site. 7-Oxygenated substrates, in contrast to
steroids, interact with 11bHSD1 with their A-ring orientated toward
the interior of the binding pocket, in agreement with models in other
species [21,30,35]. The higher Kmvalues describing metabolism of 7-
oxysterols compared with glucocorticoids, however, indicated they
were poorer afﬁnity substrates. Circulating concentrations of 7-
oxysterols in the mouse were comparable in magnitude to those in
other species [34] and increased in hyperlipidaemia [10]. However,
it is likely metabolism by 11bHSD1 would not proceed at maximal
velocity in the presence of the endogenous concentrations reported
here or by others [34,36].
While disruption of 11bHSD1 only tended to alter circulating 7-
oxysterol levels subtly [29], it substantially lowered the levels in
hepatic sub-cellular fractions. Oxysterols can be synthesized from
spontaneous oxidation of cholesterol and are derived in large part
from dietary sources [10]. Therefore the reduction in absolute
levels may arise because Hsd11b1/ mice have an improved
metabolic proﬁle with lower circulating cholesterol concentrations
[37], and thus less precursor for auto-oxidation. The speciﬁc
contribution of 11bHSD1 to the proportions of 7-keto and hydroxy
oxysterols was revealed in the increase in the ratio of 7KC/7bOHC
ratio in plasma and microsomes, following targeted disruption of
Hsd11b1, suggesting that 11bHSD1 catalyses reduction of 7KC invivo. This corroborates previous studies in rats in which hepatic
7KC accumulated following administration of the non-speciﬁc
11bHSD inhibitor carbenoxolone [9]. Lack of NADPH supply due to
genetic disruption of H6pdh again increased the 7KC/7bOHC ratio,
conﬁrming in vitro ﬁndings [38] that H6PDH promotes catalysis of
7KC to form 7bOHC in vivo, similarly to glucocorticoids. Indeed,
H6PDH appeared to be the only source of co-factor, as double
knockout of H6pdh and Hsd11b1, yielded the same ratio of 7-
oxysterols, as with disruption of H6pdh alone.
11bHSD1 may therefore play a similar role in regulating actions
of 7-oxysterols in vivo as it does glucocorticoids. The importance of
metabolism of glucocorticoids by 11bHSD1 is readily apparent
since the 11-keto steroid is inert and the hydroxy form is active.
However, distinct biological roles for 7KC and 7bOHC are not
established and a target receptor has not been deﬁned, although
there are a number of reports of subtle differences in their actions
(e.g. 7bOHC has a greater ability than 7KC to induce apoptosis in
human umbilical vein endothelial cells [39]). However 7-oxyster-
ols can be subject to further metabolism and recent reports suggest
that the 25- and 27-hydroxy metabolites of 7a- and 7bOHC play
potential roles in regulating the immune response via the novel G-
protein coupled receptor, EB12 [40,41]. Interestingly there is one
report showing that 7KC but not 7bOHC limits SCAP exit from the
ER within cells [42], which further prevents excess synthesis of
cholesterol. Hence, it follows that the increased proportion of 7KC
to 7bOHC upon inhibition of 11bHSD1 in vivo may exert a brake on
cholesterol synthesis. Other oxysterols modulate nuclear hormone
signaling pathways, but the possibility of activation of LXR, at least,
by 7-oxysterols has largely dismissed [20].
Work with cells stably transfected to express human 11bHSD1
or with adipocytes [20] has shown that 7-oxysterols (in keeping
with other 7-hydroxylated substrates [7]) may compete differen-
tially with glucocorticoids for metabolism by 11bHSD1 and thus
modulate glucocorticoid action. Inhibition appears cell-type
speciﬁc, potentially explained by differential metabolism, accu-
mulation or export of oxysterols [10]; adipocytes and macrophages
sequester oxysterols readily [10] whereas macrophages export
7KC and other oxysterols via the ABCG1 transporter [43]. Bala´zs
et al. did not detect any inhibition of human 11bHSD1 reductase
activity in lysates or HEK293 cells by 7KC or 7bOHC, but showed an
inhibition of 11bHSD1-reductase activity by 7KC (IC50
8.1  0.9 mM) in differentiated THP-1 macrophages [21]. Inhibition
of glucocorticoid metabolism by co-incubation with 7-oxysterols was
investigated here using three models of murine 11bHSD1, in all of
which reduction of glucocorticoids was favored. Our data concur with
the proposal that 7-oxysterols compete with glucocorticoids for
metabolism, with 7KC being consistently less effective at inhibiting
11-DHC reduction by isolated enzyme in vitro, than 7bOHC was at
preventing oxidation. Taking into account the IC50 values, inhibition
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However, at concentrations in the low micromolar range, as seen in
atherosclerosis [44,45], 7bOHC or 7KC may compete for oxidation
preventing glucocorticoid inactivation or reduction, respectively.
7bOHC is highly abundant in fatty streaks in developing lesions
[46,47] and the 7bOH/7KC ratio is increased. If 7bOHC dominates
to inhibit glucocorticoid oxidation, the cells in the lesion and
adjacent normal intima may become exposed to increased local
glucocorticoid levels, with adverse consequences [48]. However,
when endogenous 7-oxysterols were enriched secondary to
cholesterol loading in cultured cells, the predominant effect was
to suppress reduction of glucocorticoids, suggesting protection
from excess glucocorticoid. These ﬁndings concur with reduction
of 7KC being the major route of metabolism of 7-oxysterols in vivo.
In conclusion, 7KC and 7bOHC are poor afﬁnity substrates for
murine 11bHSD1 and are interconverted at a slower rate than
glucocorticoids. While differences exist in the patterns of in vitro and
in vivo metabolism, reduction of 7KC to 7bOHC appears the
predominant reaction in vivo. Although it seems unlikely that the
competition with oxysterols will determine predominant direction
for glucocorticoid metabolism by 11bHSD1 in health, it may play a
role in hyperlipidaemia and atherosclerosis. A greater knowledge of
the actions of these 7-oxysterols is required to fully understand the
consequences of inhibition or over-activity of 11bHSD1 pathway.
Acknowledgements
We are grateful to the Wellcome Trust Clinical Research Facility
Mass Spectrometry Core (Mrs Alison Rutter) for technical
assistance. This work was supported by grants from the Wellcome
Trust (TM, RA, PWFH, SP, BRW), British Heart Foundation (RA, DC,
PWFH, BW) and Medical Research Council David Philips fellowship
(GGL, NS).
References
[1] Kotelevtsev YV, Holmes MC, Burchell A, Houston PM, Scholl D, Jamieson PM,
et al. 11b-Hydroxysteroid dehydrogenase type 1 knockout mice show atten-
uated glucocorticoid inducible responses and resist hyperglycaemia on obesity
and stress. Proc Natl Acad Sci U S A 1997;94:14924–29.
[2] Morton NM, Paterson JM, Masuzaki H, Holmes MC, Staels B, Fievet C, et al.
Novel adipose tissue-mediated resistance to diet-induced visceral obesity in
11beta-hydroxysteroid dehydrogenase type 1-deﬁcient mice. Diabetes
2004;53:931–8.
[3] Rosenstock J, Banarer S, Fonseca VA, Inzucchi SE, Sun W, Yao W, et al. The 11-
beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves
hyperglycemia in patients with Type 2 diabetes inadequately controlled by
metformin monotherapy. Diabetes Care 2010;33:1516–22.
[4] Hermanowski-Vosatka A, Balkovec JM, Cheng K, Chen HY, Hernandez M, Koo
GC, et al. 11b-HSD1 inhibition ameliorates metabolic syndrome and prevents
progression of atherosclerosis in mice. J Exp Med 2005;202:517–27.
[5] Kipari T, Hadoke PWF, Iqbal J, Man TY, Miller E, Coutinho AE. 11b-hydro-
xysteroid dehydrogenase type 1 deﬁciency reduces atherosclerosis and plaque
inﬂammation independent of risk factors: key role of the lesional environ-
ment. FASEB Journal; http://dx.doi.org/10.1096/fj.12-219105, in press.
[6] Luo MJ, Thieringer R, Springer MS, Wright SD, Hermanowski-Vosatka A, Plump
A, et al. 11b-HSD1 inhibition reduces atherosclerosis in mice by altering pro-
inﬂammatory gene expression in the vasculature. Physiol Genomics
2013;45:47–57.
[7] Robinzon B, Michael KK, Ripp SL, Winters sj. Prough RA glucocorticoids inhibit
interconversion of 7-hydroxy and 7-oxo metabolites of dehydroepiandroster-
one: a role for 11beta-hydroxysteroid dehydrogenases? Arch Biochem Biophys
2003;412:251–8.
[8] Hult M, Elleby B, Shafqat N, Svensson S, Rane A, Jornvall H, et al. Human and
rodent type 1 11b-hydroxysteroid dehydrogenases are 7b-hydroxycholes-
terol dehydrogenases involved in oxysterol metabolism. Cell Mol Life Sci
2004;61:992–9.
[9] Schweizer RA, Zurcher M, Balazs Z, Dick B, Odermatt A. Rapid hepatic metabo-
lism of 7-ketocholesterol by 11beta-hydroxysteroid dehydrogenase type 1:
species-speciﬁc differences between the rat human, and hamster enzyme. J
Biol Chem 2004;279:18425–34.
[10] Brown AJ, Jessup W. Oxysterols Sources, cellular storage and metabolism, and
new insights into their roles in cholesterol homeostasis. Mol Aspects Med
2009;30:111–22.[11] Morton NM. Obesity and corticosteroids: 11b-hydroxysteroid type 1 as a
cause and therapeutic target in metabolic disease. Mol Cell Endocrinol
2010;316:154–64.
[12] Brown AJ, Leong SL, Dean RT, Jessup W. 7-Hydroperoxycholesterol and its
products in oxidized low density lipoprotein and human atherosclerotic
plaque. J Lipid Res 1997;38:1730–45.
[13] Song W, Chen J, Dean WL, Redinger RN, Prough RA. Puriﬁcation and charac-
terization of hamster liver microsomal 7alpha- hydroxycholesterol dehydro-
genase: similarity to type I 11beta-hydroxysteroid dehydrogenase. J Biol Chem
1998;273:16223–28.
[14] Maeda Y, Nagatomo H, Uchiyama F, Yamada M, Shiotsuki H, Ohta Y, et al. A
comparative study of the conversion of 7-hydroxycholesterol in rabbit, guinea
pig, rat, hamster and chicken. Steroids 2002;67:703–8.
[15] Bujalska IJ, Walker EA, Hewison M, Stewart PM. A switch in dehydrogenase to
reductase activity of 11b-hydroxysteroid dehydrogenase type 1 upon differ-
entiation of human omental adipose stromal cells. J Clin Endocrinol Metab
2002;87:1205–10.
[16] Hughes KA, Manolopoulos KN, Iqbal J, Cruden NL, Stimson RH, Reynolds RM,
et al. Recycling between cortisol and cortisone in human splanchnic,
subcutaneous adipose and skeletal muscle tissues in vivo. Diabetes
2012;61:1357–64.
[17] Draper N, Walker EA, Bujalska IJ, Tomlinson JW, Chalder SM, Arlt W, et al.
Mutations in the genes encoding 11b-hydroxysteroid dehydrogenase type 1
and hexose-6-phosphate dehydrogenase interact to cause cortisone reductase
deﬁciency. Nature Genet 2003;34:434–9.
[18] Lavery GG, Walker EA, Draper N, Jeyasuria P, Marcos J, Shackleton CHL, et al.
Hexose-6-phosphate dehydrogenase knock-out mice lack 11b-hydroxyster-
oid dehydrogenase type 1-mediated glucocorticoid generation. J Biol Chem
2006;281:6546–51.
[19] McNeilly AD, MacFarlane DP, O’Flaherty EN, Livingstone DEW, MacKenzie SM,
Mitic T, et al. Bile acids modulate glucocorticoid metabolism and the hypo-
thalamic-pituitary-adrenal axis in obstructive jaundice. J Hepatol
2010;52:705–11.
[20] Wamil M, Andrew R, Chapman KE, Street J, Morton NM, Seckl JR. 7-Oxysterols
modulate glucocorticoid activity in adipocytes through competition for
11beta-hydroxysteroid dehydrogenase type 1. Endocrinology 2008;149:
5909–18.
[21] Balazs Z, Nashev LG, Chandsawangbhuwan C, Baker ME, Odermatt A. Hexose-
6-phosphate dehydrogenase modulates the effect of inhibitors and alternative
substrates of 11b-hydroxysteroid dehydrogenase 1. Mol Cell Endocrinol
2009;301:117–22.
[22] Brown RW, Chapman KE, Edwards CRW, Seckl JR. Human placental 11b-
hydroxysteroid dehydrogenase: evidence for and partial puriﬁcation of a
distinct NAD-dependent isoform. Endocrinology 1993;132:2614–21.
[23] Semjonous NM, Sherlock M, Jeyasuria P, Parker KL, Walker EA, Stewart PM,
et al. Hexose-6-phosphate dehydrogenase contributes to skeletal muscle
homeostasis independent of 11b-hydroxysteroid dehydrogenase type 1. En-
docrinology 2011;152:93–102.
[24] Webster SP, Ward P, Binnie M, Craigie E, McConnell KM, Sooy K, et al.
Discovery and biological evaluation of adamantyl amide 11beta-HSD1 inhi-
bitors. Bioorg Med Chem Lett 2007;17:2838–43.
[25] Freeman NE, Rusinol AE, Linton M, Hachey DL, Fazio S, Sinensky MS, et al. Acyl-
coenzyme A: cholesterol acyltransferase promotes oxidized LDL/oxysterol-
induced apoptosis in macrophages. J Lipid Res 2005;46:1933–43.
[26] Klein U, Gimpl G, Fahrenholz F. lteration of the myometrial plasma membrane
cholesterol content with b-cyclodextrin modulates the binding afﬁnity of the
oxytocin receptor. Biochemistry 1995;34:13784–93.
[27] Kritharides L, Jessup W, Mander EL, Dean RT. Apolipoprotein A-I-mediated
efﬂux of sterols from oxidized LDL-loaded macrophages. Arterioscler Thromb
Vasc Biol 1995;15:276–89.
[28] Dzeletovic S, Breuer O, Lund E, Diczfalusy U. Determination of cholesterol
oxidation products in human plasma by isotope dilution-mass spectrometry.
Anal Biochem 1995;225:73–80.
[29] Mitic T, Andrew R, Walker BR, Hadoke PWF. Inter-conversion of 7-ketocho-
lesterol and 7b-hydroxycholesterol by 11b-HSD1 in the mouse aortic wall:
implications for vascular function. Biochimie 2013;95:548e555.
[30] Zhang J, Osslund TD, Plant MH, Clogston CI, Nybo RE, Xiong F, et al. Crystal
structure of murine 11b-hydroxysteroid dehydrogenase 1: an important
therapeutic target for diabetes. Biochemistry 2005;44:6948–57.
[31] Tanaka N, Nonaka T, Tanabe T, Yoshimoto T, Tsuru D, Mitsui Y. Crystal
structures of the binary and ternary complexes of 7 alpha-hydroxysteroid
dehydrogenase from Escherichia coli. Biochemistry 1996;35:7715–30.
[32] Christy C, Hadoke PWF, Paterson JM, Mullins JJ, Seckl JR, Walker BR. Gluco-
corticoid action in mouse aorta; localisation of 11b-hydroxysteroid dehydro-
genase type 2 and effects on responses to glucocorticoids in vitro.
Hypertension 2003;42:580–7.
[33] Filling C, Berndt KD, Benach J, Knapp S, Prozorovski T, Nordling E, et al. Critical
residues for structure and catalysis in short-chain dehydrogenases/reductases.
J Biol Chem 2002;277:25677–84.
[34] Iuliano L, Michelatta F, Natoli S, Ginanni Corradini SIM, Elisei W, Giovannelli L,
et al. Measurement of oxysterols and a-tocopherol in plasma and tissue
samples as indices of oxidant stress status. Anal Biochem 2003;312:217–23.
[35] Odermatt A, Atanasov AG, Balazs Z, Schweizer RA, Nashev LG, Schuster D, et al.
Why is 11beta-hydroxysteroid dehydrogenase type 1 facing the endoplasmic
reticulum lumen? Physiological relevance of the membrane topology of
11beta-HSD1. Mol Cell Endocrinol 2006;248:15–23.
T. Mitic´ et al. / Biochemical Pharmacology 86 (2013) 146–153 153[36] Brown AJ, Jessup W. Oxysterols and atherosclerosis. Atherosclerosis 1999;142:
1–28.
[37] Morton NM, Holmes MC, Fievet C, Staels B, Tailleux A, Mullins JJ, et al.
Improved lipid and lipoprotein proﬁle, hepatic insulin sensitivity and glucose
tolerance in 11b-hydroxysteroid dehydrogenase 1 knockout mice. J Biol Chem
2001;276:41293–300.
[38] Atanasov AG, Nashev LG, Schweizer RA, Frick C, Odermatt A. Hexose-6-
phosphate dehydrogenase determines the reaction direction of 11b-hydro-
xysteroid dehydrogenase type 1 as an oxoreductase. FEBS Lett 2004;571:
129–33.
[39] Steffen Y, Wiswedel I, Peter D, Schewe T, Sies H. Cytotoxicity of myeloperox-
idase/nitrite-oxidized low-density lipoprotein toward endothelial cells is due
to a high 7b-hydroxycholesterol to 7-ketocholesterol ratio. Free Radic Biol
Med 2006;41:1139–50.
[40] Liu C, Yang XV, Wu J, Kuei C, Mani NS, Zhang L, et al. Oxysterols direct B-cell
migration through EBI2. Nature 2011;475:519–23.
[41] Hannedouche S, Zhang J, Yi T, Shen W, Nguyen D, Pereira JP, et al. Oxysterols
direct immune cell migration via EBI2. Nature 2011;475:524–7.
[42] Brown AJ, Sun L, Feramisco JD, Brown MS, Goldstein JL. Cholesterol addition to
ER membranes alters conformation of SCAP the SREBP escort protein that
regulates cholesterol metabolism. Mol Cell 2002;10:237–45.[43] Terasaka N, Wang N, Yvan-Charvet L, Tall AR. High-density lipoprotein pro-
tects macrophages from oxidized low-density lipoprotein-induced apoptosis
by promoting efﬂux of 7-ketocholesterol via ABCG1. Proc Natl Acad Sci U S A
2007;104:15093–98.
[44] Hitsumoto T, Takahashi M, Lizuka T, Shirai K. Clinical signiﬁcance of serum 7-
ketocholesterol concentrations in the progression of coronary atherosclerosis.
J Atheroscler Thromb 2009;16:363–70.
[45] Prunet C, Petit JM, Ecarnot-Laubriet A, Athias A, Miguel-Alfonsi C, Rohmer JF,
et al. High circulating levels of 7b- and 7a-hydroxycholesterol and presence of
apoptotic and oxidative markers in arterial lesions of normocholesterolemic
atherosclerotic patients undergoing endarterectomy. Pathol Biol (Paris)
2006;54:22–32.
[46] Carpenter KL, Taylor SE, van der Veen C, Williamson BK. Lipids and oxidised
lipids in human atherosclerotic lesions at different stages of development.
Biochim Biophys Acta 1995;1256:141–50.
[47] Garcia-Cruset S, Carpenter KL, GuardiolaF. Stein BK, Mitchinson MJ. Oxysterol
proﬁles of normal human arteries fatty streaks and advanced lesions. Free
Radic Res 2001;35:31–41.
[48] Hadoke PWF, Macdonald LJ, Logie JJ, Small GR, Dover AR, Walker BR. Intra-
vascular glucocorticoid metabolism as a modulator of vascular structure and
function. Cell Mol Life Sci 2006;63:565–78.
